Related Experiment Video
Updated: Oct 6, 2025

Improved Renal Denervation Mitigated Hypertension Induced by Angiotensin II Infusion
Published on: May 26, 2022
Finerenone: A Novel Mineralocorticoid Receptor Antagonist for Cardiorenal Protection in CKD and T2DM
1Massachusetts College of Pharmacy and Health Sciences, Boston, MA, USA.
Objective:
To describe the pharmacology, clinical and safety evidence, and relevance to clinical practice of finerenone.
Data Sources:
A literature search was conducted utilizing PubMed, MEDLINE, and clinicaltrials.gov with search terms of "finerenone" and "BAY94-8862."
Study Selection And Data Extraction:
All available studies with human participants in English were considered. Studies were included if they investigated drug pharmacology, efficacy, and safety information.
Data Synthesis:
In addition to standard of care with a renin-angiotensin system inhibitor (RASi), finerenone lowered the risk of kidney disease progression (17.8% vs 21.1%) in patients with type 2 diabetes mellitus and chronic kidney disease compared to placebo. Similarly, finerenone reduced cardiovascular risk in patients with type 2 diabetes mellitus and chronic kidney disease compared to placebo (12.4% vs 14.2%).
Relevance To Patient Care And Clinical Practice:
It is anticipated that finerenone will be added to therapy after a RASi and a sodium-glucose cotransporter-2 inhibitor, as tolerated, based on adverse events and potassium levels.
Conclusions:
Finerenone offers a unique approach to further delay the progression of chronic kidney disease in patients with type 2 diabetes mellitus. It also provides another option for patients who cannot tolerate RASi or sodium-glucose cotransporter-2 inhibitors.
Related Concept Videos
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System
Heart Failure Drugs: Diuretics
Antihypertensive Drugs: Direct Renin Inhibitors
Renal Failure: Dose Adjustments
Reduced renal clearance and elimination rate are common outcomes of renal impairment. These alterations lead to a prolonged elimination half-life and an altered apparent volume of distribution for drugs. As a result, dosage adjustments are typically necessary to maintain optimal drug levels in the body.
However, dosage adjustments...
Heart Failure V: Medical Management
Chronic Kidney Disease III: Interprofessional Care

